Ultragenyx Pharmaceutical reported $283M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Kyowa Hakko Kirin JPY 94.9B 28B Sep/2026
MacroGenics USD 25.15M 17.72M Sep/2026
Moderna USD 1.18B 223M Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026